The cost-effectiveness of C-reactive protein testing and rosuvastatin treatment for patients with normal cholesterol levels

Journal of the American College of Cardiology

Volumn 57, Issue 7, 2011, Pages 784-791

  Choudhry, Niteesh K ^a   Patrick, Amanda R ^a   Glynn, Robert J ^a   Avorn, Jerry ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

cost effectiveness; hs CRP; statin

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; ROSUVASTATIN;

ADULT; ARTICLE; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DEEP VEIN THROMBOSIS; DIABETES MELLITUS; DRUG COST; FEMALE; HEART FUNCTION TEST; HEART INFARCTION; HEART MUSCLE REVASCULARIZATION; HIGH SENSITIVITY C REACTIVE PROTEIN TESTING; HUMAN; LUNG EMBOLISM; MAJOR CLINICAL STUDY; MALE; MYOPATHY; PATIENT CARE; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RHABDOMYOLYSIS; SCORING SYSTEM; SENSITIVITY ANALYSIS; STROKE; TREATMENT PLANNING; UNSPECIFIED SIDE EFFECT; UNSTABLE ANGINA PECTORIS; VENOUS THROMBOEMBOLISM;

C-REACTIVE PROTEIN; CHOLESTEROL, LDL; CORONARY DISEASE; COST-BENEFIT ANALYSIS; FEMALE; FLUOROBENZENES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; MALE; MIDDLE AGED; PYRIMIDINES; SULFONAMIDES;

EID: 79851488664     PISSN: 07351097     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jacc.2010.07.059     Document Type: Article

References (26)

1. M.A. Albert, E. Danielson, N. Rifai, and P.M. Ridker Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study JAMA 286 2001 64 70 (Pubitemid 32606333)
2. P.M. Ridker, E. Danielson, and F.A. Fonseca Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein N Engl J Med 359 2008 2195 2207
3. R.J. Glynn, E. Danielson, and F.A. Fonseca A randomized trial of rosuvastatin in the prevention of venous thromboembolism N Engl J Med 360 2009 1851 1861
4. M.A. Hlatky Expanding the orbit of primary preventionmoving beyond JUPITER N Engl J Med 359 2008 2280 2282
5. V. Vaccarino, J.D. Bremner, and M.E. Kelley JUPITER: a few words of caution Circ Cardiovasc Qual Outcomes 2 2009 286 288
6. P.M. Ridker, F.A. Fonseca, and J. Genest Baseline characteristics of participants in the JUPITER trial, a randomized placebo-controlled primary prevention trial of statin therapy among individuals with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein Am J Cardiol 100 2007 1659 1664 (Pubitemid 350122337)
7. E.D. Michos, and R.S. Blumenthal Prevalence of low low-density lipoprotein cholesterol with elevated high sensitivity C-reactive protein in the U.S.: implications of the JUPITER (Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin) study J Am Coll Cardiol 53 2009 931 935
8. R.B. D'Agostino, P.A. Wolf, A.J. Belanger, and W.B. Kannel Stroke risk profile: adjustment for antihypertensive medication. The Framingham Study Stroke 25 1994 40 43
9. N.I. Parikh, P. Gona, and M.G. Larson Long-term trends in myocardial infarction incidence and case fatality in the National Heart, Lung, and Blood Institute's Framingham Heart study Circulation 119 2009 1203 1210
10. A.W. Tsai, M. Cushman, W.D. Rosamond, S.R. Heckbert, J.F. Polak, and A.R. Folsom Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology Arch Intern Med 162 2002 1182 1189 (Pubitemid 34522408)
11. E. Arias United States Life Tables, 2002 2004 National Center for Health Statistics Hyattsville, MD
12. K.D. Kochanek, S.L. Murphy, R.N. Anderston, and C. Scott Deaths: Final Data for 2002 National Vital Statistics Reports 53 2004 National Center for Health Statistics Hyattsville, MD 1 116
13. P.M. Ridker, J.G. MacFadyen, and F.A.H. Fonseca Number needed to treat with rosuvastatin to prevent first cardiovascular events and death among men and women with low low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: Justification for the Use of statins in Prevention: an Intervention Trial Evaluating Rosuvastatin (JUPITER) Circ Cardiovasc Qual Outcomes 2 2009 616 623
14. M.J. Pletcher, L. Lazar, and K. Bibbins-Domingo Comparing impact and cost-effectiveness of primary prevention strategies for lipid-lowering Ann Intern Med 150 2009 243 254
15. Centers for Medicare & Medicaid Services Clinical Laboratory Fee Schedule https://www.cms.gov/ClinicalLabFeeSched/02-clinlab.asp#TopOfPage Accessed July 14, 2009
16. Drugstore.com website. Available at: http://www.drugstore.com. Accessed July 14, 2009.
17. A. Laupacis, D. Feeny, A.S. Detsky, and P.X. Tugwell How attractive does a new technology have to be to warrant adoption and utilization? Tentative guidelines for using clinical and economic evaluations CMAJ 146 1992 473 481
18. J. Genest, R. McPherson, and J. Frohlich 2009 Canadian Cardiovascular Society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult: 2009 recommendations Can J Cardiol 25 2009 567 579
19. G.L. Myers, R.H. Christenson, and M. Cushman National Academy of Clinical Biochemistry Laboratory Medicine Practice guidelines: emerging biomarkers for primary prevention of cardiovascular disease Clin Chem 55 2009 378 384
20. T.A. Pearson, G.A. Mensah, and R.W. Alexander Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association Circulation 107 2003 499 511 (Pubitemid 36158056)
21. N. Calonge, D.B. Petitti, T.G. DeWitt U.S. Preventive Services Task Force Using nontraditional risk factors in coronary heart disease risk assessment: U.S. Preventive Services Task Force recommendation statement Ann Intern Med 151 2009 474 482
22. P. Thavendiranathan, A. Bagai, M.A. Brookhart, and N.K. Choudhry Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials Arch Intern Med 166 2006 2307 2313 (Pubitemid 44833354)
23. B. Freidlin, and E.L. Korn Stopping clinical trials early for benefit: impact on estimation Clin Trials 6 2009 119 125
24. G.J. Blake, P.M. Ridker, and K.M. Kuntz Potential cost-effectiveness of C-reactive protein screening followed by targeted statin therapy for the primary prevention of cardiovascular disease among patients without overt hyperlipidemia Am J Med 114 2003 485 494 (Pubitemid 36515111)
25. P.M. Ridker, N. Rifai, and M. Clearfield Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events N Engl J Med 344 2001 1959 1965 (Pubitemid 32568149)
26. B. Mihaylova, A. Briggs, J. Armitage, S. Parish, A. Gray, R. Collins Heart Protection Study Collaborative Lifetime cost effectiveness of simvastatin in a range of risk groups and age groups derived from a randomised trial of 20,536 people BMJ 333 2006 1145